How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

July 29, 2015

Targeted Therapies and their Impact on Melanoma

Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.

July 25, 2018

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.